Life Summary
Park Young-kun is the CEO of GeneOne Life Science. He also serves as the CEO of its subsidiary, VGXI.

He is accelerating efforts to secure orders for plasmid DNA, a key raw material for gene therapies and DNA vaccines.

Born on March 25, 1964, he is a Korean-American who immigrated to the United States with his parents when he was in the first year of middle school.

He graduated from Dickinson College with a degree in economics, completed an MBA program at MIT Sloan School of Management, and earned a J.D. from the University of Pennsylvania Law School, obtaining his U.S. attorney license.

He established his own law firm, Law Office Y.K. PARK.

He was a founding member and vice president of VGX Pharmaceuticals, a subsidiary of U.S. biotech company Inovio. After serving as an in-house legal counsel and director at GeneOne Life Science, which was acquired by Inovio, he became CEO in 2011. That same year, he also assumed the role of CEO at its subsidiary, VGXI.

He possesses perseverance and drive, seeing every endeavor through to the end.

#ParkYoungkun #GeneOneLifeScience #VGXI #biotechnology #DNAvaccine #genetherapy #plasmidDNA #Inovio #biopharmaceuticals #CEO